



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

PATENT

Applicant: L. Alani, et al.

Serial No.: 09/576,097

Filed: May 22, 2000

For: IMPROVED PHARMACEUTICAL
FORMULATIONS

Examiner: D. Lukton

Group Art Unit: 1653

Docket No.: 6499.US.02

Date: May 17, 2002

Certificate of Mailing (37 C.F.R. 1.8(a))

I hereby certify that this paper (along with
any paper referred to as being attached or
enclosed) is being deposited with the United
States Postal Service on the date shown below
with sufficient postage as first class mail in an
envelope addressed to the:

Commissioner for Patents
Washington, D. C. 20231, on:

Date of Deposit: May 17, 2002

Wanda C. Smith 5/17/02
Wanda E. Smith Date

AMENDMENT AND RESPONSECommissioner for Patents
Washington, D.C. 20231**RECEIVED**

MAY 28 2002

Dear Sir:

TECH CENTER 1600/2900

Please amend this application as follows:

IN THE CLAIMS:

Please cancel, without prejudice to the patentability thereof, Claims 2, 12 and 13.

91

1. (amended) A pharmaceutical composition comprising:
 - (a) solubilized ritonavir or a combination of solubilized ritonavir and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in the amount of from about 1% to about 50% by weight of the total solution;
 - (b) a pharmaceutically acceptable organic solvent which comprises a medium and/or long chain fatty acid or a mixture thereof in the amount of from about 40% to about 75% by weight of the total solution, and ethanol or propylene glycol in the amount of from about 1% to about 15% by weight of the total solution;
 - (c) water in the amount of from about 0.4% to about 3.5% by weight of the total solution;
and
 - (d) optionally, a pharmaceutically acceptable surfactant.